Alchemia and Dr. Reddy's Laboratories Ltd. Expand Fondaparinux Marketing Collaboration

Published: Jul 15, 2010

BRISBANE, Australia--(BUSINESS WIRE)--Alchemia (ASX:ACL) today announced the agreement of terms with Dr Reddy’s Limited for marketing fondaparinux sodium for injection (the generic version of GlaxoSmithKline’s Arixtra®) in all territories outside of North America. This agreement does not in any way alter the existing arrangements between the companies for the manufacture and North American marketing of fondaparinux.

Back to news